Atlas Trials

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Clinical trial NCT03602560 · COMPLETED

Trial details

NCT number
NCT03602560
Sponsor
Gilead Sciences
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Biliary Cholangitis
Start date
2018-10-01
Primary completion
2020-02-16
Enrollment
265

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.